Eli Lilly’s Rezvoglar Receives the US FDA’s Approval as Second Interchangeable Insulin Biosimilar for Diabetes Mellitus
Shots:
- The US FDA has approved Rezvoglar, a second interchangeable biosimilar insulin product to Lantus (insulin glargine) for diabetes mellitus, based on Semglee which the US FDA approved on July 28, 2021. Rezvoglar (SC, QD) is available in 3mL prefilled pens
- The biosimilar is a long-acting human insulin analog that can help improve glycemic control in adult and pediatric patients with T2D. The company has previously approved insulin glargine-aglr as a biosimilar to insulin glargine on Dec 17, 2021
- Greater availability of biosimilar and interchangeable insulin products may provide more treatment options for patients with the potential to lower treatment costs and allow greater access to more individuals
Ref: Centerforbiosimilars | Image: Eli Lilly
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
